Allopurinol
- Generic Name
- Allopurinol
- Brand Names
- Aloprim, Zyloprim
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4O
- CAS Number
- 315-30-0
- Unique Ingredient Identifier
- 63CZ7GJN5I
- Background
Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .
...
- Indication
Allopurinol is indicated in :
1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
...
- Associated Conditions
- Hyperuricemia, Primary Gout, Recurrent calcium oxalate calculi, Secondary gout, Calcium oxalate calculi Renal Calculi
- Associated Therapies
- -
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 780
- Registration Number
- NCT04956432
- Locations
- 🇨🇳
RenJi Hospital, Shanghai JiaoTong University School Of Medicine, Shanghai, Shanghai, China
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 650
- Registration Number
- NCT04875702
- Locations
- 🇺🇸
West Virginia University (Including Mobile Clinical Trials Unit), Morgantown, West Virginia, United States
🇺🇸The University of Alabama at Birmingham, South Birmingham, Alabama, United States
🇺🇸UCLA Health, Santa Monica, California, United States
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 294878
- Registration Number
- NCT04746989
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT04532918
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 159
- Registration Number
- NCT04327024
- Locations
- 🇸🇰
Research Site, Svidnik, Slovakia
A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT04256629
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
- Conditions
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- dr. M.J.N.L. Benders
- Target Recruit Count
- 236
- Registration Number
- NCT04217421
- Locations
- 🇳🇱
University Medical Center Groningen (UMCG), Groningen, Netherlands
🇳🇱Radboud University Medical Center Nijmegen (Radboudumc), Nijmegen, Netherlands
🇳🇱Erasmus Medical Center Rotterdam (Erasmus MC), Rotterdam, Netherlands
Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm
- Conditions
- Interventions
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 165
- Registration Number
- NCT04026776
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
- Conditions
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 861
- Registration Number
- NCT03990363
- Locations
- 🇪🇸
Research Site, Valencia, Spain
Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 17
- Registration Number
- NCT03865407
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.